The glomerulopathy of sickle cell disease

Kenneth I Ataga, Vimal K Derebail, David R Archer, Kenneth I Ataga, Vimal K Derebail, David R Archer

Abstract

Sickle cell disease (SCD) produces many structural and functional abnormalities in the kidney, including glomerular abnormalities. Albuminuria is the most common manifestation of glomerular damage, with a prevalence between 26 and 68% in adult patients. The pathophysiology of albuminuria in SCD is likely multifactorial, with contributions from hyperfiltration, glomerular hypertension, ischemia-reperfusion injury, oxidative stress, decreased nitric oxide (NO) bioavailability, and endothelial dysfunction. Although its natural history in SCD remains inadequately defined, albuminuria is associated with increased echocardiography-derived tricuspid regurgitant jet velocity, systemic blood pressure, and hypertension, as well as history of stroke, suggesting a shared vasculopathic pathophysiology. While most patients with albuminuria are treated with angiotensin converting enzyme inhibitors/angiotensin receptor blockers, there are no published long-term data on the efficacy of these agents. With the improved patient survival following kidney transplantation, SCD patients with end-stage renal disease should be considered for this treatment modality. Given the high prevalence of albuminuria and its association with multiple SCD-related clinical complications, additional studies are needed to answer several clinically important questions in a bid to adequately elucidate its pathophysiology, natural history, and treatment.

© 2014 The Authors American Journal of Hematology Published by Wiley Periodicals, Inc.

Figures

Figure 1
Figure 1
Proposed mechanisms of glomerulopathy in sickle cell disease. Multiple mechanisms may contribute to the pathogenesis of glomerular damage in sickle cell disease. These may occur due to changes in the renal vasculature, peritubular capillaries and the glomerulus. PG: prostaglandins; NO: nitric oxide; ANP: atrial natriuretic peptide; ROS: reactive oxygen species; sFLT-1: soluble fms-like tyrosine kinase-1; VEGF: vascular endothelial growth factor; ANG-II: angiotensin II; TGF-β: transforming growth factor-β; TNFα: tumor necrosis factor-α; ET-1: endothelin-1.

References

    1. Ataga KI, Orringer EP. Renal abnormalities in sickle cell disease. Am J Hematol. 2000;63:205–211.
    1. Falk RJ, Jenette JC. Renal disease. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, editors. Sickle Cell Disease: Basic Principles and Clinical Practice. New York: Raven Press; 1994. pp. 673–680.
    1. Sears DA. The morbidity of sickle cell trait: A review of the literature. Am J Med. 1978;64:1021–1036.
    1. Kiryluk K, Jadoon A, Gupta M, Radhakrishnan J. Sickle cell trait and gross hematuria. Kidney Int. 2007;71:706–710.
    1. Statius van Eps LW, Pinedo-Veels C, de Vries CH. Nature of concentrating defect in sickle cell nephropathy, microangiographic studies. Lancet. 1970;1:450–452.
    1. Serjeant GR. Sickle Cell Disease. Oxford: Oxford University Press; 1992. pp. 261–281.
    1. Falk RJ, Scheinman J, Phillips G. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. N Engl J Med. 1992;326:910–915.
    1. Bhathena DB, Sondheimer JH. The glomerulopathy of homozygous sickle hemoglobin (SS) disease: Morphology and pathogenesis. J Am Soc Nephrol. 1991;1:1241–1252.
    1. Maigne G, Ferlicot S, Galacteros F. Glomerular lesions in patients with sickle cell disease. Medicine (Baltimore) 2010;89:18–27.
    1. Nasr SH, Markowitz GS, Sentman RL, D'Agati VD. Sickle cell disease, nephrotic syndrome, and renal failure. Kidney Int. 2006;69:1276–1280.
    1. De Paepe ME, Trudel M. The transgenic SAD mouse: A model of human sickle cell glomerulopathy. Kidney Int. 1994;46:1337–1345.
    1. Paszty C, Brion CM, Manci E. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science. 1997;278:876–878.
    1. Diwan BA, Gladwin MT, Noguchi CT. Renal pathology in hemizygous sickle cell mice. Toxicol Pathol. 2002;30:254–262.
    1. Allon M, Lawson L, Eckman JR. Effects of nonsteroidal anti-inflammatory drugs on renal function in sickle cell anemia. Kidney Int. 1988;34:500–506.
    1. Thompson J, Reid M, Hambleton I, Serjeant GR. Albuminuria and renal function in homozygous sickle cell disease: Observations from a cohort study. Arch Intern Med. 2007;167:701–708.
    1. Haymann JP, Stankovic K, Levy P. Glomerular hyperfiltration in adult sickle cell anemia: A frequent hemolysis associated feature. Clin J Am Soc Nephrol. 2010;5:756–761.
    1. Aygun B, Mortier NA, Smeltzer MP. Glomerular hyperfiltration and albuminuria in children with sickle cell anemia. Pediatr Nephrol. 2011;26:1285–1290.
    1. King L, MooSang M, Miller M, Reid M. Prevalence and predictors of microalbuminuria in Jamaican children with sickle cell disease. Arch Dis Child. 2011;96:1135–1139.
    1. Hostetter TH, Olson JL, Rennke HG. Hyperfiltration in remnant nephrons: A potential adverse response to renal ablation. Am J Physiol. 1981;241:F85–F93.
    1. Olson JL, Hostetter TH, Rennke HG. Altered glomerular permselectivity and progressive sclerosis following extreme ablation of renal mass. Kidney Int. 1982;22:112–126.
    1. Nath KA, Grande JP, Haggard JJ. Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am J Pathol. 2001;158:893–903.
    1. Nath KA, Grande JP, Croatt AJ. Transgenic sickle mice are markedly sensitive to renal ischemia-reperfusion injury. Am J Pathol. 2005;166:963–972.
    1. Juncos JP, Grande JP, Croatt AJ. Early and prominent alterations in hemodynamics, signaling, gene expression following renal ischemia in sickle cell disease. Am J Physiol. 2010;298:F892–F899.
    1. Roy S, Konstantinidis DG, Rizvi T. Increased oxidative stress in sickle cell disease activates the renin-angiotensin-TGF-β pathway to mediate sickle nephropathy. Annual Meeting of the American Society of Hematology. 2013 et al.. Abstract # 2211.
    1. Ataga KI, Brittain JE, Moore D. Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: potential role of soluble fms-like tyrosis kinase-1. Eur J Haematol. 2010;85:257–263.
    1. Becton LJ, Kalpatthi RV, Rackoff E. Prevalence and clinical correlates of microalbuminuria in children with sickle cell disease. Pediatr Nephrol. 2010;25:1505–1511.
    1. Gurkan S, Scarponi KJ, Hotchkiss H. Lactate dehydrogenase as a predictor of kidney involvement in patients with sickle cell anemia. Pedriatr Nephrol. 2010;25:2123–2127.
    1. Maier-Redelsperger M, Levy P, Lionnet F. Strong association between a new marker of hemolysis and glomerulopathy in sickle cell anemia. Blood Cells Mol Dis. 2010;45:289–292.
    1. Day TG, Drasar ER, Fulford T. Association between hemolysis and albuminuria in adults with sickle cell anemia. Haematologica. 2012;97:201–205.
    1. Weber ML, Vang D, Velho PE. Morphine promotes renal pathology in sickle mice. Int J Nephrol Renovasc Dis. 2012;5:109–118.
    1. de Jong PE, Statius van Epps LW. Sickle cell nephropathy: New insights into its pathophysiology. Kidney Int. 1985;27:711–717.
    1. Scheinman JI. Sickle cell disease and the kidney. Nat Clin Prac. 2009;5:78–88.
    1. Landburg PP, Elsenga H, Schnog JB. Increased serum levels of anti-angiogenic factors soluble fms-like tyrosine kinase and soluble endoglin in sickle cell disease. Acta Haematol. 2008;120:130–133.
    1. Ataga KI, Brittain JE, Jones SK. Association of soluble fms-like tyrosine kinase-1 with pulmonary hypertension and haemolysis in sickle cell disease. Br J Haematol. 2011;152:485–491.
    1. Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligand VEGFB and PlGF: Drug targets for anti-angiogenic therapy? Nat Rev Cancer. 2008;8:942–956.
    1. Dimmeler S, Dernbach E, Zeiher AM. Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett. 2000;477:258–262.
    1. Ahmed A. New insights into the etiology of preeclampsia: Identification of key elusive factors for the vascular complications. Thromb Res. 2011;127:S72–S75. (Suppl 3):
    1. Guasch A, Navarete J, Nass K, Zayas CF. Glomerular involvement in adults with sickle cell hemoglobinopathies: Prevalence and clinical correlates of progressive renal failure. J Am Soc Nephrol. 2006;17:2228–2235.
    1. Asnani MR, Fraser RA, Reid ME. Higher rates of hemolysis are not associated with albuminuria in Jamaicans with sickle cell disease. PLoS One. 2011;6:e18863.
    1. Gurbanov K, Rubinstein I, Hoffman A. Differential regulation of renal regional blood flow by endothelin-1. Am J Physiol. 1996;271:F1166–F1172.
    1. Heyman SN, Khamaisi M, Rosen S, Rosenberger C. Renal parenchymal hypoxia, hypoxia response and the progression of chronic kidney disease. Am J Nephrol. 2008;28:998–1006.
    1. Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol. 2008;294:F1–F9.
    1. Zatz R, Baylis C. Chronic nitric oxide inhibition model six years on. Hypertension. 1998;32:958–964.
    1. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21:37–47.
    1. Lima CS, Bottini PV, Garlipp CR. Accuracy of the urinary albumin to creatinine ratio as a predictor of albuminuria in adults with sickle cell disease. J Clin Pathol. 2002;55:973–975.
    1. Alvarez O, Montane B, Lopez G. Early blood transfusions protect against microalbuminuria in children with sickle cell disease. Pediatr Blood Cancer. 2006;47:71–76.
    1. Dharnidharka VR, Dabbagh S, Atiyeh B. Prevalence of microalbuminuria in children with sickle cell disease. Pediatr Nephrol. 1998;12:475–478.
    1. Wigfall DR, Ware RE, Burchinal MR. Prevalence and clinical correlates of glomerulopathy in children with sickle cell disease. J Pediatr. 2000;136:749–753.
    1. McBurney PG, Hanevold CD, Hernandez CM. Risk factors for microalbuminuria in children with sickle cell anemia. J Pediatr Hematol Oncol. 2002;24:473–477.
    1. McKie KT, Hanevold CD, Hernandez C. Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease. J Pediatr Hematol Oncol. 2007;29:140–144.
    1. McPherson Yee M, Jabbar SF, Osunkwo I. Chronic kidney disease and albuminuria in children with sickle cell disease. Clin J Am Soc Nephrol. 2011;6:2628–2633.
    1. Iwalokun BA, Iwalokun SO, Hodonu SO. Evaluation of microalbuminuria in relation to asymptomatic bacteruria in Nigerian patients with sickle cell anemia. Saudi J Kidney Dis Transpl. 2012;23:1320–1330.
    1. Aleem A. Proteinuria in adult Saudi patients with sickle cell disease is not associated with identifiable risk factors. Saudi J Kidney Dis Transpl. 2010;21:903–908.
    1. Laurin LP, Nachman PH, Desai PC. Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. Nephrol Dial Transplant. 2013 et al.. [Epub ahead of print]
    1. Powars DR, Elliot-Mills DD, Chan L. Chronic renal failure in sickle cell disease: Risk factors, clinical course, and mortality. Ann Intern Med. 1991;115:614–616.
    1. Alvarez O, Lopez-Mitnik G, Zilleruelo G. Short-term follow up of patients with sickle cell disease and albuminuria. Pediatr Blood Cancer. 2008;50:1236–1239.
    1. Gosmanova EO, Zaidi S, Wan JY, Adams-Graves PE. Prevalence and progression of chronic kidney disease in adult patients with sickle cell disease. J Investig Med. 2014 [Epub ahead of print]
    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
    1. De Castro LM, Jonassaint JC, Graham FL. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am J Hematol. 2008;83:19–25.
    1. Forrest S, Kim A, Carbonella J, Pashankar F. Proteinuria is associated with elevated tricuspid regurgitant jet velocity in children with sickle cell disease. Pediatr Blood Cancer. 2012;58:937–940.
    1. Bolarinwa RA, Akinlade KS, Kuti MA. Renal disease in adult Nigerians with sickle cell anemia: A report of prevalence, clinical features and risk factors. Saudi J Kidney Dis Transpl. 2012;23:171–175.
    1. Elmariah H, Garrett ME, De Castro LM. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol. 2014;89:530–535.
    1. Aoki RY, Saad ST. Enalapril reduces the albuminuria of patients with sickle cell disease. Am J Med. 1995;98:432–435.
    1. Foucan L, Bourhis V, Bangou J. A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia. Am J Med. 1998;104:339–342.
    1. Fitzhugh CD, Wigfall DR, Ware RE. Enalapril and hydroxyurea therapy for children with sickle nephropathy. Pediatr Blood Cancer. 2005;45:982–985.
    1. Aygun B, Mortier NA, Smeltzer MP. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. Am J Hematol. 2013;88:116–119.
    1. De Jong PE, De Jong-Van Den Berg TW, Sewrajsingh GS. The influence of indomethacin on renal haemodynamics in sickle cell anaemia. Clin Sci. 1980;59:245–250.
    1. Allon M, Lawson L, Eckman JR. Effects of nonsteroidal anti-inflammatory drugs on renal function in sickle cell anemia. Kidney Int. 1988;34:500–506.
    1. Wong W, Elliot-Mills D, Powars D. Renal failure in sickle cell anemia. Hematol Oncol Clin North Am. 1996;10:1321–1331.
    1. Rodgers GP, Walker EC, Podgor MJ. Is “relative” hypertension a risk factor for vaso-occlusive complications in sickle cell disease? Am J Med Sci. 1993;305:150–156.
    1. Gordeuk VR, Sachdev V, Taylor JG. Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency. Am J Hematol. 2008;83:15–18.
    1. Lemonne N, Romana M, Lamarre Y. Association between relative systemic hypertension and otologic disorders in patients with sickle cell-hemoglobin C disorder. Am J Hematol. 2014;89:667. et al.. [Epub ahead of print]
    1. Lamarre Y, Lalanne-Mistrih ML, Romana M. Male gender, increased blood viscosity, body mass index and triglyceride levels are independently associated with systemic relative hypertension in sickle cell anemia. PLoS One. 2013;8:e66004.
    1. McClellan AC, Luthi JC, Lynch JR. High one year mortality in adults with sickle cell disease and end-stage renal disease. Br J Haematol. 2012;159:360–367.
    1. Nissenson AR, Port FK. Outcome of end-stage renal disease in patients with rare causes of renal failure. I. Inherited and metabolic disorders. Q J Med. 1989;73:1055–1062.
    1. Chatterjee SN. National study in natural history of renal allografts in sickle cell disease or trait: A second report. Transplant Proc. 1987;19:33–35.
    1. Ojo AO, Govaerts TC, Schmouder RL. Renal transplantation in end-stage sickle cell nephropathy. Transplantation. 1999;67:291–295.
    1. Bleyer AJ, Donaldson LA, McIntosh M. Relationship between underlying renal disease and renal transplantation outcome. Am J Kidney Dis. 2001;37:1152–1161.
    1. Nair R, Walker PD. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney Int. 2006;69:1455–1458.
    1. Pham PT, Pham PC. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence. Nephrol Dial Transplant. 2012;27:2965–2971.
    1. Huang E, Parke C, Mehrnia A. Improved survival among sickle cell kidney transplant recipients in the recent era. Nephrol Dial Transplant. 2013;28:1039–1046.
    1. Spector D, Zachary JB, Sterioff S, Millan J. Painful crises following renal transplantation in sickle cell anemia. Am J Med. 1978;64:835–839.
    1. Donnelly PK, Edmunds ME, O'Reilly K. Renal transplantation in sickle cell disease. Lancet. 1988;2:229.
    1. Miner DJ, Jorkasky DK, Perloff LJ. Recurrent sickle cell nephropathy in a transplanted kidney. Am J Kidney Dis. 1987;10:306–313.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다